Pharma companies who want to keep the prices of their medicines private in Germany may soon be able to do so – as long as they meet certain conditions.
The market access landscape in Germany is particularly interesting in 2021, as a key component – AMNOG – is ten years old, and that milestone prompts reflections on what has worked well and